GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has submitted the Marketing Authorisation Application (MAA) for its lead product LUMEVOQ® to the European Medicines Agency (EMA), seeking approval for the treatment of patients with vision loss due to Leber Hereditary Optic Neuropathy (LHON) caused by mutation in the ND4 mitochondrial gene.
"This first regulatory submission for GenSight is a major milestone in our progression from a pure research organization to one with commercial capabilities. It validates a technology platform that has the potential to address the high unmet medical needs of patients suffering from a range of rare diseases. I would like to thank all GenSight employees and partners whose motivation, focus and effort made this submission possible,” said Bernard Gilly, Co-founder and Chief Executive Officer of GenSight Biologics.
LHON is a rare, mitochondrial genetic disease, mainly affecting young males. The ND4 mutation results in the worst visual outcomes, with most patients becoming legally blind. There continues to be a high unmet medical need for the 800-1200 new LHON patients in Europe and the U.S. each year, particularly those who are struck blind in their prime working years.
Lenadogene nolparvovec (tradename: LUMEVOQ®) is a recombinant adeno-associated viral vector, serotype 2 (rAAV2/2), containing a cDNA encoding the human wild-type mitochondrial NADH dehydrogenase 4 protein (ND4), which has been specifically developed for the treatment of LHON associated with mutation in the ND4 gene. It received orphan drug designation status for the treatment of LHON from the EMA in 2011 and from the U.S. Food and Drug Administration (FDA) in 2013.
GenSight submitted the MAA based on the benefit-risk balance established by results from a Phase-I/IIa study (CLIN-01), two pivotal Phase-III efficacy studies (CLIN-03A: RESCUE, and CLIN-03B: REVERSE) and the long-term follow up study of RESCUE and REVERSE (CLIN 06 - readout at Year 3 post injection). To demonstrate the efficacy of LUMEVOQ® in the context of a contralateral effect, the Company used a statistics-based indirect comparison methodology to assess the visual outcomes in LUMEVOQ®-treated patients (from LUMEVOQ® efficacy studies) against those in untreated patients from Natural History studies and GenSight’s REALITY Natural History Registry.
GenSight expects to submit the Biologics License Application (BLA) for LUMEVOQ® to the FDA in H2 2021. First-in-human data from GenSight’s second clinical stage program, GS030, are expected to be available in H2 2021.
About GenSight Biologics GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, LUMEVOQ® (GS010; lenadogene nolparvovec), is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to the eye by intravitreal injection to offer patients a sustainable functional visual recovery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200914005857/en/
The company recorded $798 million in gross merchandise volume (GMV) for the third quarter Farfetch agreed a new partnership with Alibaba and Richemont to create a “Luxury New Retail” platform Farfetch stock price is up more than 300% since the beginning of this year Farfetch (NYSE: FTCH) stock price has exploded this month to print record highs above the $50 mark. This way, shares are now up over 300% since the beginning of the year. Fundamental analysis: Sales soar Farfetch, an online luxury fashion platform, posted a loss of $537 million to beat the market’s expectations for the third quarter. The company recorded $798 million in gross merchandise volume (GMV), which is by far the highest number reached in a single quarter so far. Are you looking for fast-news, hot-tips and market analysis? Sign-up for the Invezz newsletter, today. “We believe we’re witnessing a paradigm shift in the way people buy luxury. From day one, Farfetch set out the differentiated vision to enable the luxury industry by building a full suite of capabilities to connect the creators, curators and consumers, who are the lifeblood of the luxury industry,” Jose Neves, the Founder, Co-Chairman & Chief Executive Officer
Save on a range of Bose headphones deals at the Black Friday 2020 sale, featuring the top Sport Earbuds, Bose 700 and more deals
Black Friday 2020 researchers have found the latest Bose headphones deals for Black Friday, together with sales on QuietComfort Earbuds, QC35 and more. Access the best deals listed below.
Best Bose Deals:
Save up to 43% on the latest Bose headphones, speakers & soundbars at Walmart - check the latest deals on the best-selling Bose QuietComfort 35 & Earbuds, Bose Headphones 700, SoundLink, SoundSport & more
Save up to 33% off on Bose noise cancelling headphones, Bluetooth speakers & Bose Frames at Dell.com - check the latest deals on Bose noise cancelling headphones, Bluetooth audio sunglasses and multimedia speaker systems from Bose
Save up to 41% on Bose wireless noise canceling headphones, speakers, soundbars & home theater systems at Amazon - check live prices on Bose Headphones 700, Bose QuietComfort 35, SoundSport & SoundLink headphones, soundbars & speakers
Save up to 50% on Bose headphones, speakers & soundbars at Bose.com - check the latest deals on the Bose official online store
Save on Bose speakers, wireless & noise cancelling headphones at Verizon - click the link to see latest deals on Bose Soundsport and Bose Homespeaker
Save up to 39% on a wide range of Bose wireless speakers at Walmart - check the latest deals on Bose Bluetooth portable speakers, home surround sound systems and more
Save up to 25% off on Bose speakers, soundbars & home theater systems at Dell.com - check the latest deals on multimedia speaker systems, smart speakers and more top Bose audio gear
Save up to 40% on Bose SoundLink, SoundTouch & Home speakers at Amazon - check the latest deals on a wide range of Bose portable, wireless & home surround sound speakers
Save up to 43% on Bose wireless & noise canceling headphones & earbuds at Walmart - check the latest deals on Bose 700, QuietComfort 35 (QC35) and SoundSport Free True wireless earbuds
Save up to 34% on Bose noise cancelling headphones at Dell.com - get top-rated Bose headphones at discounted prices including Bose QuietComfort35, Bose 700 noise-cancelling headphones, Bose Sport Earbuds & more
Save up to 30% on Bose earbuds including Bose SoundSport wireless in-ear headphones & Bose Sport Earbuds at Dell.com - save on the all-new Bose Sport Earbuds as well as the top-rated Bose SoundSport earbuds
Save up to $150 on Bose QuietComfort (QC35) headphones & earbuds at Walmart
Save $100 on Bose QuietComfort 35 II wireless noise cancelling headphones at Dell.com - check the latest deals on Bose’s top-rated noise cancelling headphones
In need of some more deals? Click here to shop the entire selection of live deals at Walmart’s Black Friday sale and click here to see Amazon’s latest Black Friday deals. Retail Fuse earns commissions from purchases made using the links provided.
About Retail Fuse: Retail Fuse reports the latest retail news. As an Amazon Associate and affiliate Retail Fuse earns from qualifying purchases.
Contact: Andy Mathews (firstname.lastname@example.org)